Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 23Colorectal Neoplasms 19Carcinoma, Hepatocellular 19Triple Negative Breast Neoplasms 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Renal Cell 13Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Recurrence 6Lymphoma, Extranodal NK-T-Cell 6Lung Neoplasms 6Locally Advanced Rectal Cancer 6Breast Neoplasms 6Advanced Solid Tumor 6Ovarian Neoplasms 5Glioblastoma 5Endometrial Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Nasopharyngeal Neoplasms 4

Interventions

Doxorubicin 2spartalizumab 1selinexor 1ribociclib 1pazopanib 1STA 9090 1Proton Therapy 1Paclitaxel 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disorders of Sex Development × spartalizumab × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡